Alzheimer's disease (AD) is the primary cause of dementia and is characterized by the death
of brain cells due to the accumulation of insoluble amyloid plaques, hyperphosphorylation of …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder with an
irreversible, progressive, and untreatable nature that causes progressive deterioration, loss …

Background Alzheimer's disease (AD) is the leading cause of dementia. Currently, there are
no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been …

In Alzheimer's disease (AD), the accumulation of amyloid-β plaques, overactivity of MAO-B,
and phosphorylated tau protein in the central nervous system result in neuroinflammation …

Alzheimer's disease is a fatal illness associated with two persistent problems in treatment i.
ineffective drug transportation across the bio-membranes and ii. on-site targeting. Such …

Neurodegenerative disorders, such as Alzheimer's disease (AD), present biomedical
challenges due to inability of pharmaceuticals to permeate the blood-brain barrier (BBB) and …

With the aging of the world population, there has been a notable increase in the incidence of
Alzheimer disease (AD), the most prevalent neurodegenerative disease affecting the elderly …

Aim To prepare polymer-drug conjugates containing a combination of memantine, tacrine,
and E)-N-(3-aminopropyl) cinnamide, promising therapeutics for the treatment of …

Alzheimer's disease (AD) is related to the anomalous binding that occurs between amyloid-β
peptide (Aβ) and copper ion, through imidazole ring of histidine (His), as stated in the …

Internal aqueous phase was incorporated in solid lipid nanoparticles (SLNs) containing 5
lipid components to form dual-phase SLNs (DPSLNs), which were then conjugated with …